inhaler

吸入器
  • 文章类型: Journal Article
    本研究旨在分析质量,可靠性,以及针对父母和儿童的小儿哮喘吸入器技术的YouTube视频内容。这项研究有一个描述性的,回顾性,和横截面设计。这项研究是通过使用“儿科定量吸入器,\"\"儿科Accuhaler,“和”儿科Diskus。“视频的受欢迎程度是使用视频功率指数衡量的。使用改进的DISCERN和全球质量量表(GQS)评估视频的质量和可靠性。这项研究分析了55个关于儿科吸入器技术的YouTube视频。总的来说,其中19个视频与带有用于潮气呼吸的垫片的加压定量吸入器(pMDI)有关,14个带垫片的pMDI吸入器,用于单次呼吸,和22个diskus设备。研究结果表明,演示使用pMDI设备进行单次呼吸的视频具有更可靠的修改后的DISCERN评分。然而,与潮汐呼吸相关的视频比显示使用diskus设备和pMDI单次呼吸的视频更受欢迎。根据diskus设备上的视频清单,错误率最高的步骤是“检查剂量计数器”为72.7%和“轻轻呼气”,远离吸入器的比例为63.6%。在改良的DISCERN评分和GQS之间观察到中度相关性。虽然关于pMDI单次呼吸技术的YouTube视频可能对儿科患者和护理人员有用,对他们来说,从他们的医疗保健提供者那里接受吸入器技术教育是至关重要的。这项研究的发现对儿科患者和护理人员具有重要意义。特别是那些依赖YouTube获取健康相关信息的人。
    UNASSIGNED: Proper technique for using inhalers is crucial in treating pediatric asthma. YouTube offers a wide range of videos on pediatric inhaler technique, but there is a need to analyze the quality, reliability, and content of these resources.
    UNASSIGNED: This study aims to analyze the quality, reliability, and content of YouTube videos on pediatric asthma inhaler techniques.
    UNASSIGNED: The study has a descriptive, retrospective, and cross-sectional design. The research was conducted by searching YouTube using the \"Pediatric Metered Dose Inhaler,\" \"Pediatric Accuhaler,\" and \"Pediatric Diskus.\" The video\'s popularity was measured using the Video Power Index. The quality and reliability of the videos were evaluated using the modified DISCERN and Global Quality Scale (GQS).
    UNASSIGNED: This study analyzed 55 YouTube videos on the pediatric inhaler technique. 19 of the videos were related to the pMDI inhaler with a spacer for tidal breathing, 14 pMDI inhaler with a spacer for single breath, and 22 diskus device. Findings show that videos demonstrating the use of pMDI devices for single breath have more reliable modified DISCERN scores. However, videos related to tidal breathing are more popular than those showing the use of diskus devices and single breath. Based on the checklist for videos on diskus devices, the steps with the highest error rates are \'Check dose counter\' at 72.7% and \'Breathe out gently, away from the inhaler\' at 63.6%. A moderate correlation was observed between the modified DISCERN score and the GQS.
    UNASSIGNED: While YouTube videos on the pMDI single-breath technique may be useful for pediatric patients and caregivers, it is crucial for them to receive inhaler technique education from their healthcare provider. This study\'s findings hold great significance for pediatric patients and caregivers, particularly those who rely on YouTube for health-related information.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:用于治疗哮喘和慢性阻塞性肺疾病(COPD)的大多数药物是通过定量吸入器(MDI)服用的。研究报告说,大多数患者表现出较差的吸入器技术,导致疾病控制不佳。数字健康应用程序有可能改善吸入药物的技术和依从性。
    目的:本研究旨在验证BreatheSuiteMDI装置在评估通过MDI服用剂量技术方面的有效性。
    方法:本研究为验证性研究。从纽芬兰和拉布拉多的社区药房招募了30名自我报告哮喘或COPD诊断的参与者,加拿大。参与者使用与安慰剂MDI相连的BreatheSuiteMDI设备,类似于服用3剂。药剂师使用评分表来评估使用MDI的技术。一位独立研究人员将药剂师评分表的结果与BreatheSuite设备的结果进行了比较。
    结果:这项研究发现,BreatheSuiteMDI可以客观地检测MDI技术中的几个错误。BreatheSuiteMDI设备记录的数据显示,所有参与者在使用MDI时至少出现一次错误。与单独观察相比,BreatheSuite设备捕获了大约40%(143/360)的误差。BreatheSuite记录的MDI步骤错误的参与者的分布与仅观察报告的错误相比如下:启动前的摇动,33.3%(30/90)与25.5%(23/90);驱动期间吸入器的直立方向,66.7%(60/90)与18.87%(17/90);协调(吸入开始后启动),76.6%(69/90)与35.5%(32/90);灵感持续时间,96.7%(87/90)与34.4%(31/90)。
    结论:BreatheSuiteMDI可以客观地检测MDI技术中的几个错误,仅通过观察就错过了。它有可能提高慢性肺部疾病患者的治疗效果。
    BACKGROUND: The majority of medications used in treating asthma and chronic obstructive pulmonary disease (COPD) are taken through metered-dose inhalers (MDIs). Studies have reported that most patients demonstrate poor inhaler technique, which has resulted in poor disease control. Digital Health applications have the potential to improve the technique and adherence of inhaled medications.
    OBJECTIVE: This study aimed to validate the effectiveness of the BreatheSuite MDI device in assessing the technique of taking a dose via an MDI.
    METHODS: The study was a validation study. Thirty participants who self-reported a diagnosis of asthma or COPD were recruited from community pharmacies in Newfoundland and Labrador, Canada. Participants used a BreatheSuite MDI device attached to a placebo MDI and resembled taking 3 doses. Pharmacists used a scoring sheet to evaluate the technique of using the MDI. An independent researcher compared the results of the pharmacist\'s scoring sheet with the results of the BreatheSuite device.
    RESULTS: This study found that the BreatheSuite MDI can objectively detect several errors in the MDI technique. The data recorded by the BreatheSuite MDI device showed that all participants performed at least one error in using the MDI. The BreatheSuite device captured approximately 40% (143/360) more errors compared to observation alone. The distribution of participants who performed errors in MDI steps as recorded by BreatheSuite compared to errors reported by observation alone were as follows: shaking before actuation, 33.3% (30/90) versus 25.5% (23/90); upright orientation of the inhaler during actuation, 66.7% (60/90) versus 18.87% (17/90); coordination (actuating after the start of inhalation), 76.6% (69/90) versus 35.5% (32/90); and duration of inspiration, 96.7% (87/90) versus 34.4% (31/90).
    CONCLUSIONS: The BreatheSuite MDI can objectively detect several errors in the MDI technique, which were missed by observation alone. It has the potential to enhance treatment outcomes among patients with chronic lung diseases.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    吸入器在慢性阻塞性肺疾病(COPD)患者的治疗中的次优使用可能是住院患者中一个主要但记录较少的问题。我们旨在描述在普通内科住院的COPD患者中滥用吸入器的患病率。
    我们在2022年8月至2023年4月期间在弗里堡医院内科部门连续诊断为COPD并住院的患者中进行了单中心横断面研究。瑞士。使用In-CheckDialG16®对患者的吸入器技术和峰值吸气流量(PIF)进行评估。主要结果是滥用吸入器的患病率,定义为使用严重错误和/或PIF不足的吸入器。次要结果包括不适合患者特征的吸入器和使用至少一种误用吸入器的患者的患病率。
    该研究包括96例患者和160例吸入器在入院时进行评估。在这些吸入器中,111(69.4%;95%置信区间[CI]61.6-76.4)被滥用;105(65.6%;95%CI57.7-72.9)由于吸入技术存在严重错误,22(13.8%;95%CI8.8-20.1)由于PIF不足。关于次要结果,27个吸入器(16.9%)不适合,79个患者(82.3%)使用至少一个误用吸入器。
    在诊断为COPD的住院患者中,三分之二的吸入器被滥用。次优使用主要是由于存在严重错误,但也存在不足的PIF和不合适的吸入器。
    UNASSIGNED: The suboptimal use of inhalers in the treatment of patients with chronic obstructive pulmonary disease (COPD) is probably a major but poorly documented problem in hospitalized patients. We aimed to describe the prevalence of misused inhalers among patients hospitalized with COPD in a department of general internal medicine.
    UNASSIGNED: We conducted a monocentric cross-sectional study in consecutive patients with a diagnosis of COPD and hospitalized between August 2022 and April 2023 in the internal medicine division of Fribourg Hospital, Switzerland. Patients underwent an assessment of their inhaler technique and peak inspiratory flow (PIF) using the In-Check Dial G16®. The primary outcome was the prevalence of misused inhalers, defined as an inhaler used with a critical error and/or insufficient PIF. Secondary outcomes included the prevalence of inhalers unsuitable to patients\' characteristics and of patients using at least one misused inhaler.
    UNASSIGNED: The study included 96 patients and 160 inhalers were assessed at admission. Among these inhalers, 111 (69.4%; 95% confidence interval [CI] 61.6-76.4) were misused; 105 (65.6%; 95% CI 57.7-72.9) due to the presence of a critical error in the inhalation technique and 22 (13.8%; 95% CI 8.8-20.1) due to insufficient PIF. Concerning the secondary outcome, 27 inhalers (16.9%) were unsuitable, and 79 patients (82.3%) used at least one misused inhaler.
    UNASSIGNED: Among patients hospitalized with a diagnosis of COPD, two-thirds of inhalers were misused. Suboptimal use was mainly due to the presence of critical errors, but also to the presence of an insufficient PIF and unsuitable inhalers.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    BACKGROUND: Poor disease control in patients with chronic obstructive pulmonary disease (COPD) is associated with suboptimal inhaler use.
    OBJECTIVE: This study was designed to explore the accuracy of inhaler use and related factors in elderly patients with COPD.
    METHODS: A cross-sectional survey design was used to recruit patients with COPD from a medical centre in southern Taiwan who were over 65 years old and used inhalers regularly. All of the data as well as information on inhaler use accuracy were collected using a self-designed questionnaire and inhaler operation checklist. Multivariable logistic regression was used to analyse significant correlates of correct inhaler operation.
    RESULTS: The average age of the 150 participants was 75.0 years (SD = 7.5) years. Most used one type of inhaler only (86.0%). The rate of accurate inhaler operation was 40.7% (n = 61) for the sample, with dry powder inhalers associated with the highest accuracy (64%) and pressurized metered-dose inhalers associated with the lowest accuracy (1.6%). Multivariate logistic regression analysis showed that using a soft mist inhaler (adjusted odds ratio, AOR = 23.29; 95% confidence interval, 95% CI [2.84, 191.07]), using a dry powder inhaler (AOR =15.60, 95% CI [1.99, 122.26]), and higher satisfaction with the inhaler were positively and independently associated with accurate inhaler use (AOR = 1.94, 95% CI [1.09, 3.44]).
    CONCLUSIONS: Important factors related to inhaler use accuracy include inhaler type and level of patient satisfaction with their inhaler. Healthcare professionals should regularly confirm that older patients are able to use their inhalers correctly and are satisfied with their inhalers.
    BACKGROUND: 老年慢性阻塞性肺疾病病人吸入器操作正確性及相關因素.
    UNASSIGNED: 慢性阻塞性肺疾病控制不良與病人吸入器使用錯誤有關。.
    UNASSIGNED: 探討老年慢性阻塞性肺疾病病人操作吸入器正確性及相關因素。.
    UNASSIGNED: 橫斷調查性研究設計,以南部某醫學中心65 歲以上且使用吸入器治療的慢性阻塞性肺疾病病人。用自擬問卷與吸入器操作檢核表收集資料及評估吸入器操作正確性。用多變量邏輯迴歸分析吸入器操作正確性相關因素。.
    UNASSIGNED: 150位病人平均年齡75.0歲(SD = 7.5),多數病人僅用一種吸入器(86.0%)。吸入器操作正確者佔40.7%(n = 61),操作乾粉吸入器正確者比率最高(64%)、加壓計量吸入器正確者比率最低(1.6%)。使用軟霧吸入器者(adjusted odds ratio, AOR = 23.29; 95% confidence interval, 95% CI [2.84, 191.07])與乾粉吸入器者(AOR = 15.60, 95% CI [1.99, 122.26])操作正確勝算比顯著高於使用加壓計量吸入器者;對吸入器滿意度分數越高者,操作正確勝算比越高(AOR = 1.94, 95% CI [1.09, 3.44])。.
    UNASSIGNED: 吸入器操作正確性的重要相關因素為吸入器種類及對吸入器滿意度。醫護人員應定期確認老年病人能正確使用吸入器並對吸入器感到滿意。.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    呼吸医学中的移动健康(mHealth)技术是一项快速增长且有前途的技术,在患者和医疗保健提供者(HCP)中很受欢迎。他们为正确的吸入技术提供提醒和分步说明,监测患者对治疗的依从性,并促进患者与HCPs之间的沟通。
    虽然多年来开发了许多mHealth应用程序,大多数应用程序没有支持证据。由于进行mHealth应用程序选择的研究有限,因此在呼吸医学中选择最佳的mHealth应用程序具有挑战性。尽管mHealth技术在呼吸医学的未来发挥着重要作用,关于肺部疾病患者的mHealth技术的评估和选择,没有单一的指南。本文旨在概述移动健康技术,特别强调数字吸入器和用于哮喘的独立应用。此外,它提供了对评估的见解,选择,以及围绕呼吸医学中mHealth应用的相关考虑。
    评估mHealth应用程序需要时间,资源,以及政府监管机构等利益相关者之间的合作,主题专家,和行业代表。填补mHealth应用程序评估和选择的空白将改善临床决策,个性化治疗,呼吸内科的自我管理和疾病监测。
    UNASSIGNED: Mobile health (mHealth) technology in respiratory medicine is a fast-growing and promising digital technology that is popular among patients and healthcare providers (HCPs). They provide reminders and step-by-step instructions for the correct inhalation technique, monitor patients\' adherence to treatment, and facilitate communication between patients and HCPs.
    UNASSIGNED: While numerous mHealth apps have been developed over the years, most applications do not have supporting evidence. Selecting the best mHealth app in respiratory medicine is challenging due to limited studies carrying out mHealth app selection. Although mHealth technologies play an important part in the future of respiratory medicine, there is no single guide on the evaluation and selection of mHealth technologies for patients with pulmonary diseases. This paper aims to provide an overview of mHealth technologies, particularly emphasizing digital inhalers and standalone applications used in asthma. Additionally, it offers insights into the evaluation, selection, and pertinent considerations surrounding mHealth applications in respiratory medicine.
    UNASSIGNED: Evaluating mHealth apps will take time, resources, and collaboration between stakeholders such as governmental regulatory bodies, subject-matter experts, and industry representatives. Filling the gaps in the evaluation and selection of the mHealth app will improve clinical decision-making, personalized treatments, self-management and disease monitoring in respiratory medicine.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    吸入治疗的疗效取决于达到适当的峰值吸气流速(PIFR),然而,在韩国,慢性阻塞性肺疾病(COPD)患者中不适当PIFR的患病率仍未被研究.这项研究旨在评估不适当的PIFR的患病率,其与COPD评估测试(CAT)得分的相关性,以及与次优PIFR相关的因素。
    我们招募了108名COPD患者,这些患者使用相同的吸入器至少一年没有加重。使用吸气流量计(In-Check™DIALG16)测量PIFR。人口统计,临床,肺功能,收集CAT评分数据。不合适的定义为:对于干功率吸入器(DPI)用户,PIFR<60L/min或对于气雾剂装置用户,PIFR>90L/min。
    该队列包括87名(80.6%)男性,平均年龄71.0±8.5岁,预测的平均支气管扩张剂后用力呼气量为69.1±1.8%。二十九人(26.9%)使用气溶胶装置,76(70.4%)使用DPI,三人(2.8%)同时使用。在17.2%的气溶胶设备用户和42.1%的DPI用户中发现了不适当的PIFR。不适当的PIFR组的CAT评分明显高于适当的PIFR组(11.2±7.7vs7.5±4.9,P=0.003)。在DPI用户中,女性,较短的高度,较低的体重和MVV(最大自主通气)与不适当的PIFR相关.
    COPD患者中不适当的PIFR患病率在气雾剂装置使用者中为17.2%,在DPI使用者中为42.1%。次优PIFR与女性性别相关,身材矮小,在DPI用户中更低的权重和MVV。
    UNASSIGNED: Inhalation therapy efficacy hinges on proper peak inspiratory flow rate (PIFR) attainment, yet the prevalence of inappropriate PIFR among patients with chronic obstructive pulmonary disease (COPD) remains unstudied in Korea. This study aimed to assess the prevalence of inappropriate PIFR, its correlation with COPD assessment test (CAT) scores, and factors associated with suboptimal PIFR.
    UNASSIGNED: We enrolled 108 patients with COPD who had been using the same inhaler for at least one year without exacerbations. PIFR was measured using an inspiratory flow meter (In-Check™ DIAL G16). Demographic, clinical, pulmonary function, and CAT score data were collected. Inappropriate was defined as PIFR < 60L/min for dry power inhaler (DPI) users or > 90L/min for aerosol device users.
    UNASSIGNED: The cohort comprised 87 (80.6%) men, mean age 71.0 ± 8.5 years, with mean post-bronchodilator forced expiratory volume in one second of 69.1 ± 1.8% predicted. Twenty-nine (26.9%) used aerosol devices, 76 (70.4%) used DPIs, and three (2.8%) used both. Inappropriate PIFRs were found in 17.2% of aerosol device users and 42.1% of DPI users. CAT scores were significantly higher in inappropriate PIFR group than appropriate PIFR group (11.2 ± 7.7 vs 7.5 ± 4.9, P = 0.003). In DPI users, female, shorter height, lower body weight and MVV (maximal voluntary ventilation) were associated with inappropriate PIFR.
    UNASSIGNED: Prevalence of inappropriate PIFR among patients with COPD is 17.2% for aerosol device users and 42.1% for DPI users. Suboptimal PIFR correlates with female gender, shorter stature, lower weight and MVV in DPI users.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    吸入皮质类固醇(ICS)是控制哮喘和预防持续性哮喘患者恶化的主要治疗方法。使用了许多类型的ICS药物,单独或与其他控制药物组合。尽管ICSs的广泛使用,在许多哮喘患者中,哮喘控制仍不理想.次优控制导致反复发作,导致频繁的急诊室就诊和住院,是由于多种因素。一个这样的因素是对于患者不适当的ICS选择。虽然存在许多针对其他因素的干预措施,不太关注不适当的ICS选择。哮喘是一种异质性疾病,具有可变的潜在炎症和生物标志物。由于ICS代谢酶的遗传变异,多达50%的哮喘患者对某些ICS表现出一定程度的抵抗或不敏感。导致对ICS的不同反应。然而,ICS选择,尤其是在初级保健环境中,通常不适合患者的特征。相反,ICS的选择在很大程度上取决于试错,通常由保险报销决定,组织规定政策,或成本,导致许多患者无法实现最佳控制的一刀切的方法。迫切需要一种决策支持工具,该工具可以在护理点预测有效的ICS,并指导提供者选择最有可能和快速缓解患者症状并改善哮喘控制的ICS。迄今为止,没有这样的工具存在。预测哪个患者对哪个ICS反应良好是开发这种工具的第一步。然而,没有研究预测ICS反应,形成一个缺口。虽然哮喘的生物学异质性很大,几个,如果有的话,生物标志物和基因型可用于系统分析所有哮喘患者并预测ICS反应。因为对所有患者进行基因分型或基因分型是不可行的,在临床护理期间收集的现成的电子健康记录数据提供了低成本,可靠,以及更全面的方式来描述所有患者。在本文中,我们指出需要开发决策支持工具来指导ICS的选择,以及在满足需求方面的差距。然后,我们概述了一种通过创建机器学习模型并应用因果推断来根据患者的特征预测患者明年的ICS反应来缩小这一差距的方法。该模型使用电子健康记录数据来表征所有患者,并提取可能反映内生型或基因型的模式。本文为未来的研究提供了路线图,最终目标是将哮喘护理从一刀切转变为个性化护理,改善结果,节省医疗资源。
    Inhaled corticosteroid (ICS) is a mainstay treatment for controlling asthma and preventing exacerbations in patients with persistent asthma. Many types of ICS drugs are used, either alone or in combination with other controller medications. Despite the widespread use of ICSs, asthma control remains suboptimal in many people with asthma. Suboptimal control leads to recurrent exacerbations, causes frequent ER visits and inpatient stays, and is due to multiple factors. One such factor is the inappropriate ICS choice for the patient. While many interventions targeting other factors exist, less attention is given to inappropriate ICS choice. Asthma is a heterogeneous disease with variable underlying inflammations and biomarkers. Up to 50% of people with asthma exhibit some degree of resistance or insensitivity to certain ICSs due to genetic variations in ICS metabolizing enzymes, leading to variable responses to ICSs. Yet, ICS choice, especially in the primary care setting, is often not tailored to the patient\'s characteristics. Instead, ICS choice is largely by trial and error and often dictated by insurance reimbursement, organizational prescribing policies, or cost, leading to a one-size-fits-all approach with many patients not achieving optimal control. There is a pressing need for a decision support tool that can predict an effective ICS at the point of care and guide providers to select the ICS that will most likely and quickly ease patient symptoms and improve asthma control. To date, no such tool exists. Predicting which patient will respond well to which ICS is the first step toward developing such a tool. However, no study has predicted ICS response, forming a gap. While the biologic heterogeneity of asthma is vast, few, if any, biomarkers and genotypes can be used to systematically profile all patients with asthma and predict ICS response. As endotyping or genotyping all patients is infeasible, readily available electronic health record data collected during clinical care offer a low-cost, reliable, and more holistic way to profile all patients. In this paper, we point out the need for developing a decision support tool to guide ICS selection and the gap in fulfilling the need. Then we outline an approach to close this gap via creating a machine learning model and applying causal inference to predict a patient\'s ICS response in the next year based on the patient\'s characteristics. The model uses electronic health record data to characterize all patients and extract patterns that could mirror endotype or genotype. This paper supplies a roadmap for future research, with the eventual goal of shifting asthma care from one-size-fits-all to personalized care, improve outcomes, and save health care resources.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    传统的计量吸入器(MDI)长期以来一直是哮喘和慢性阻塞性肺疾病(COPD)管理的基石。每年影响数百万人。尽管有其优势,患者教育的形式以及自1956年推出以来这些吸入器的设计不变,这是一个持续的挑战。MDI设计的这种缺乏进展无意中导致了异物吸入的发生。在这种情况下,我们报告了一位50岁的男性,有哮喘病史,他面临着使用吸入器吸入异物的事件。病人给他的吸入器吸了一毛钱,因为它已经被卡在装置的喉舌中,这是没有上限的。这个案子,像许多其他人一样,证明了MDI吸入器设计需要创新的变化。虽然许多文章或案例都集中在异物去除上,本病例报告的主要目的是研究旨在避免吸入事件的预防措施和解决方案。
    The conventional metered dose inhaler (MDI) has long served as a cornerstone in the management of asthma and chronic obstructive pulmonary disease (COPD), affecting millions annually. Despite its advantages, a persistent challenge is seen in the form of patient education and the unchanged design of these inhalers since their inception in 1956. This lack of progress in MDI design has inadvertently contributed to incidences of foreign body inhalation. In this case presentation we report a 50-year-old male with a past medical history of asthma, who faced an incident of foreign body inhalation with use of his inhaler. The patient aspirated a dime when he administered his inhaler, as it had become lodged in the device\'s mouthpiece, which was uncapped. This case, like many others, demonstrates the need for innovative changes in MDI inhaler design. While numerous articles or cases concentrate on foreign body removal, the primary objective of this case report is to investigate preventative measures and solutions aimed at averting incidents of inhalation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    哮喘是儿童时期最常见的慢性疾病。如果未经治疗,哮喘可导致衰弱的日常症状,影响生活质量,但更重要的是,可能导致致命的哮喘发作,不幸的是,这种发作仍在全球范围内发生。控制哮喘的最有效治疗策略是患者遵循个性化哮喘行动计划(PAAP),该计划将始终包括定期使用吸入性皮质类固醇。检查哮喘儿童的药物依从性,我们整理了该领域系统评价的最新证据,以解决以下5个关键问题;什么是依从性?是否有证据表明儿童没有坚持预防性药物治疗?为什么依从性差?依从性的障碍是什么?良好的依从性是否可以改善哮喘的结局?最后,如何提高治疗依从性?
    Asthma is the most common chronic disease in childhood. If untreated, asthma can lead to debilitating daily symptoms which affect quality of life, but more importantly can lead to fatal asthma attacks which unfortunately still occur globally. The most effective treatment strategy for controlling asthma is for the patient to follow a personalised asthma action plan (PAAP) which will invariably include regular use of an inhaled corticosteroid. To examine medication adherence in children with asthma, we collated recent evidence from systematic reviews in this area to address the following 5 key questions; What is adherence? Is there evidence that children are not adhering to preventer medication? Why is adherence poor and what are the barriers to adherence? Does good adherence improve outcomes in asthma? And lastly, how can treatment adherence be improved?
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Editorial
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号